New markers for lung disease in cystic fibrosis
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks for biological markers (substances in your body) that can show if a lung infection with Mycobacterium abscessus is getting worse. It may help researchers develop better ways to track and treat the infection in people with cystic fibrosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with cystic fibrosis.
- You are 18 years or older.
- You are being seen for routine care at a participating center.
- You understand the study and can give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special blood markers in people with cystic fibrosis who have or haven't been treated for a lung infection caused by nontuberculous mycobacteria. The goal is to better understand the body's response, which could lead to better treatments.
This study looks at how a child’s early lung function, viral infections, and gut (microbiome) changes affect cystic fibrosis over time. It may help doctors understand what predicts how lung disease develops, which could improve future care.
This trial studies blood and tissue samples from people with COPD, IPF, or lung cancer to find markers that can help diagnose and predict these conditions. It aims to discover why some lung diseases progress to cancer.
This study tests a new method to detect bacteria in the lungs of people with cystic fibrosis (CF) by analyzing mucus samples. It aims to improve how we diagnose and treat lung infections.
This trial follows people with cystic fibrosis to better understand how “nontuberculous mycobacteria” (a type of lung germ) spreads between healthcare visits and care settings. It may help improve future prevention and monitoring strategies for CF patients who have had these bacteria.
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
Hear when a new Non-Tuberculous Mycobacterial Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.